Ascelia Pharma
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar! Ascelia Pharma completes FDA Type A meeting on Orviglance NDA
Ascelia Pharma completed the previously scheduled Type A meeting with the U.S. Food and Drug Administration (FDA) on September 9, 2026, regarding the Complete Response Letter (CRL) for the Orviglance® New Drug Application (NDA).
The meeting provided an opportunity to discuss the issues raised by the FDA in the CRL and to gain further clarity regarding obtaining regulatory approval for Orviglance in the US. Ascelia will provide an update on the regulatory path forward after receiving the FDA's official meeting minutes. The minutes are expected within approximately 30 days.
| Datum | 2026-09-10, kl 07:30 |
| Källa | MFN |